Comparison timestamp: 2025-05-01 12:42:04 UTC
RestoredCDC URL: http://restoredcdc.org/www.cdc.gov/iis/code-sets/fall-season-respiratory-codes.html
Live cdc.gov URL ↗: https://www.cdc.gov/iis/code-sets/fall-season-respiratory-codes.html
RestoredCDC URL: http://restoredcdc.org/www.cdc.gov/iis/code-sets/fall-season-respiratory-codes.html
Live cdc.gov URL ↗: https://www.cdc.gov/iis/code-sets/fall-season-respiratory-codes.html
Removed: Line removed from cdc.gov. Specific word removals are highlighted.
Added: Line added to cdc.gov. Specific word additions are highlighted.
Injected:
Line or disclaimer added by RestoredCDC.org.
Unchanged: Line unchanged.
Original site: www.cdc.gov/iis/code-sets/fall-season-respiratory-codes.html | RestoredCDC.org is an independent project, not affiliated with CDC or any federal entity. Visit CDC.gov for free official information. Due to archival on January 6, 2025, recent outbreak data is unavailable. Videos are not restored. Access data.restoredcdc.org for restored data. Use of this site implies acceptance of this disclaimer.[More]About Us Report Bug Compare ContentSkip directly to site content Skip directly to search Skip directly to On This PageAn official website of the United States governmentHere's how you knowOfficial websites use .govA .gov website belongs to an official government organization in the United States.Secure .gov websites use HTTPSA lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.Immunization Information Systems (IIS)Explore TopicsSearchSearchClear InputFor Everyone* About IIS* Immunization (IZ) Gateway* Vaccine 2D Barcodes* CDC IIS Activities* Immunization Information Systems Annual Report (IISAR)* IIS Functional Standards v4.1* Functional Standards: Introduction* Functional Standards (v5.0): Introduction* Information on Vaccine Data Code Sets* Core Data Elements* Information on IIS Policy and Legislation* Contacts for IIS Immunization Records* IIS Training Resources* Clinical Decision Support for Immunization (CDSi)* IIS Technical Guidance* IIS Resources and Reference Materials* View allView Allsearch close searchsearchImmunization Information Systems (IIS) Menu CloseImmunization Information Systems (IIS) MenusearchFor Everyone* About IIS* Immunization (IZ) Gateway* Vaccine 2D Barcodes* CDC IIS Activities* Immunization Information Systems Annual Report (IISAR)* IIS Functional Standards v4.1* Functional Standards: Introduction* Functional Standards (v5.0): Introduction* Information on Vaccine Data Code Sets* Core Data Elements* View AllView All Immunization Information Systems (IIS)About IIS Immunization (IZ) Gateway Vaccine 2D Barcodes CDC IIS Activities Immunization Information Systems Annual Report (IISAR) IIS Functional Standards v4.1 Functional Standards (v5.0): Introduction Information on Vaccine Data Code Sets View AllAbout IIS Immunization (IZ) Gateway Vaccine 2D Barcodes CDC IIS Activities Immunization Information Systems Annual Report (IISAR) Functional Standards: Introduction Information on Vaccine Data Code Sets Core Data Elements View AllAugust 26, 2024Fall Season Respiratory Vaccine CodesAt a glanceThe respiratory vaccine codes and crosswalk tables for RSV, COVID-19, and Influenza are provided in the following summary tables.Respiratory Syncytial Virus (RSV) Codes and CrosswalksThe following table includes the RSV codes and crosswalks included in the CDC IIS Vaccine Code Sets. Note that the CPT codes shown are not mapped to the NDC codes, but are mapped to the CVX codes shown. CPT codes provided in the vaccine code sets are to assist with code categorizations and are not intended to represent billable codes.Get email updatesSubscribe to receive email updates about this page.Download the RSV Crosswalk tableRespiratory Syncytial Virus (RSV) Vaccine Codes Fall 2024CVX Code CVX Description Sale Proprietary Name Sale Labeler MVX Code Unit of Sale NDC11 Unit of Use NDC11 Presentation CPT Code CPT Description303 Respiratory syncytial virus (RSV), vaccine, recombinant, protein subunit RSV prefusion F, adjuvant reconstituted, 0.5 mL, preservative free Arexvy GlaxoSmithKline Biologicals SA SKB 58160-0848-11 58160-0723-03 VIAL, 0.5 mL, reconstituted 90679 Respiratory syncytial virus vaccine, preF, recombinant, subunit, adjuvanted, for intramuscular use00069-0344-01305 Respiratory syncytial virus (RSV), vaccine, bivalent, protein subunit RSV prefusion F, diluent reconstituted, 0.5 mL, preservative free Abrysvo Pfizer Laboratories Div Pfizer Inc PFR 00069-0344-05 00069-0207-01 VIAL, 0.5 mL, reconstituted 90678 Respiratory syncytial virus vaccine, preF, subunit, bivalent, for intramuscular use00069-0344-10305 Respiratory syncytial virus (RSV), vaccine, bivalent, protein subunit RSV prefusion F, diluent reconstituted, 0.5 mL, preservative free Abrysvo Pfizer Laboratories Div Pfizer Inc PFR 00069-2465-01 00069-2465-19 VIAL, 0.5 mL, SINGLE-DOSE 90678 Respiratory syncytial virus vaccine, preF, subunit, bivalent, for intramuscular use00069-2465-10326 Respiratory syncytial virus (RSV), mRNA, injectable, preservative free mRESVIA Moderna US, INC. MOD 80777-0345-96 80777-0345-01 SYRINGE, 0.5 mL 90683 Respiratory syncytial virus vaccine, mRNA lipid nanoparticles, for intramuscular use80777-0345-90Respiratory Syncytial Virus (RSV) Monoclonal Antibody Codes Fall 2024 (*)CVX Code CVX Description Sale Proprietary Name Sale Labeler MVX Code Unit of Sale NDC11 Unit of Use NDC11 Presentation CPT Code CPT Description306 Respiratory syncytial virus (RSV) monoclonal antibody, IgG1κ, (nirsevimab-alip), 0.5 mL, neonates and children to 24 months BEYFORTUS Sanofi Pasteur Inc. PMC 49281-0575-15 49281-0575-00 SYRINGE, 0.5 mL 90380 Respiratory syncytial virus, monoclonal antibody, seasonal dose; 0.5 mL dosage, for intramuscular use307 Respiratory syncytial virus (RSV) monoclonal antibody, IgG1κ, (nirsevimab-alip), 1 mL, neonates and children to 24 months BEYFORTUS Sanofi Pasteur Inc. PMC 49281-0574-15 49281-0574-88 SYRINGE, 1 mL 90381 Respiratory syncytial virus, monoclonal antibody, seasonal dose; 1 mL dosage, for intramuscular use(*) The BEYFORTUS nirsevimab monoclonal antibody codes are included in the vaccine code set in a manner similar to regular vaccines to enable reporting or other program data exchange in accordance with ACIP and CDC guidelines.Respiratory Syncytial Virus (RSV) Unspecified CodesCVX Code CVX Description CVX Note314 Respiratory syncytial virus (RSV) vaccine, unspecified Unspecified, for historic records where the specific vaccine administered is not known315 Respiratory syncytial virus (RSV) monoclonal antibody (MAB), unspecified Unspecified, for historic records where the specific RSV MAB administered is not known304 Respiratory syncytial virus (RSV), unspecified Unspecified, for historic records where it is not known if RSV vaccine or RSV MAB was administeredGuidance relating to RSV vaccines can be found at Home page for MMWR | MMWR (cdc.gov)On July 17, 2023, the Food and Drug Administration licensed Nirsevimab (Beyfortus), a long-acting monoclonal antibody for the prevention of respiratory syncytial virus (RSV) in infants and young children. It is anticipated that the Advisory Committee on Immunization Practices (ACIP) will vote on potential recommendations for use of this product and its inclusion in the Vaccines for Children (VFC) program at the August 3rd ACIP meeting.New codes listed above have been added in anticipation of potential recommendations. More information to support integration into VFC, as well as details around vaccine codes, Clinical Decision Support for Immunization (CDSi), and any data collection requirements will be published as they become available.Fall 2024 COVID-19 Vaccine Codes and CrosswalksThe following table provides a preview and summary of the vaccine codes and crosswalks for Fall 2024 COVID-19 vaccines.Note: Codes in the following table are effective and published in the full vaccine code sets only upon EUA issuance or BLA licensure of COVID-19 vaccine(s) by the Food and Drug Administration (FDA). Additional code details and fields values are included in the vaccine code sets published.Download the Fall 2024 COVID-19 Vaccine Code Crosswalk tableManufacturer (MVX) Product Label Tradename (**) CVX Code CVX Term Description CVX Short Description UoS NDC10 Packaging UoU NDC10 Age Cohort; CPT Code CPT DescriptionUoS NDC11 UoU NDC11 PresentationPfizer COMIRNATY (COVID-19 Vaccine, mRNA, 2024-2025 Formula), no freeze formulation 309 SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, tris-sucrose, 30 mcg/0.3 mL dose COVID-19, mRNA, LNP-S, PF, tris-sucrose, 30 mcg/0.3 mL SARS-CoV-2 virus strain Omicron KP.2 0069-2432-10 CARTON, 10 PRE-FILLED GLASS SYRINGES 0069-2432-01 Ages 12 years and older; 91320 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, 30 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use(PFR) 00069-2432-10 00069-2432-01 SYRINGE, PRE-FILLED, GLASS, 30 mcg/0.3 mL - DO NOT FREEZEPfizer 59267-4438-2 59267-4438-1 Ages 5 through 11 years;(PFR) Pfizer-BioNTech COVID-19 Vaccine (2024-2025 Formula) 310 SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, tris-sucrose, 10 mcg/0.3 mL dose COVID-19, mRNA, LNP-S, PF, tris-sucrose, 10 mcg/0.3 mL SARS-CoV-2 virus strain Omicron KP.2 59267-4438-02 CARTON, 10 SINGLE-DOSE VIALS 59267-4438-01 VIAL, SINGLE-DOSE, 10 mcg/0.3 mL 91319 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, 10 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular useDO NOT DILUTEPfizer Pfizer-BioNTech COVID-19 Vaccine (2024-2025 Formula) 308 SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, tris-sucrose, 3 mcg/0.3 mL dose COVID-19, mRNA, LNP-S, PF, tris-sucrose, 3 mcg/0.3 mL SARS-CoV-2 virus strain Omicron KP.2 59267-4426-2 CARTON, 10 MULTI-DOSE VIALS 59267-4426-1 Ages 6 months through 4 years; 91318 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, 3 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use(PFR) 59267-4426-02 59267-4426-01 VIAL, MULTI-DOSE, 3 DOSES, 3 mcg/0.3 mL AFTER DILUTIONModerna SPIKEVAX (COVID-19 Vaccine, mRNA, 2024-2025 Formula) 312 SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, 50 mcg/0.5 mL dose COVID-19, mRNA, LNP-S, PF, 50 mcg/0.5 mL SARS-CoV-2 virus strain Omicron KP.2 80777-110-96 CARTON, 10 PRE-FILLED SYRINGES 80777-110-01 Ages 12 years and older; 91322 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, 50 mcg/0.5 mL dosage, for intramuscular use(MOD) 80777-0110-96 80777-0110-01 SYRINGE, PRE-FILLED, 50 mcg/0.5 mLModerna SPIKEVAX (COVID-19 Vaccine, mRNA, 2024-2025 Formula) 312 SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, 50 mcg/0.5 mL dose COVID-19, mRNA, LNP-S, PF, 50 mcg/0.5 mL SARS-CoV-2 virus strain Omicron KP.2 80777-110-93 CARTON, 10 PRE-FILLED SYRINGES 80777-110-01 Ages 12 years and older; 91322 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, 50 mcg/0.5 mL dosage, for intramuscular use(MOD) 80777-0110-93 80777-0110-01 SYRINGE, PRE-FILLED, 50 mcg/0.5 mLModerna Moderna COVID-19 Vaccine (2024-2025 Formula) 311 SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, 25 mcg/0.25 mL dose COVID-19, mRNA, LNP-S, PF, 25 mcg/0.25 mL SARS-CoV-2 virus strain Omicron KP.2 80777-291-80 CARTON, 10 PRE-FILLED SYRINGES 80777-291-09 Ages 6 months through 11 years; 91321 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, 25 mcg/0.25 mL dosage, for intramuscular use(MOD) 80777-0291-80 80777-0291-09 SYRINGE, PRE-FILLED, 25 mcg/0.25 mLModerna Moderna COVID-19 Vaccine (2024-2025 Formula) 311 SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, 25 mcg/0.25 mL dose COVID-19, mRNA, LNP-S, PF, 25 mcg/0.25 mL SARS-CoV-2 virus strain Omicron KP.2 80777-291-81 CARTON, 10 BLISTER-SEALED PRE-FILLED SYRINGES 80777-291-09 Ages 6 months through 11 years; 91321 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, 25 mcg/0.25 mL dosage, for intramuscular use(MOD) 80777-0291-81 80777-0291-09 SYRINGE, PRE-FILLED, 25 mcg/0.25 mLNovavax 80631-107-10 80631-107-01 Ages 12 years and older;(NVX) Novavax COVID-19 Vaccine, Adjuvanted (2024-2025 Formula) 313 SARS-COV-2 (COVID-19) vaccine, subunit, recombinant spike protein-nanoparticle+Matrix-M1 Adjuvant, preservative free, 5 mcg/0.5 mL dose COVID-19, subunit, rS-nanoparticle, adjuvanted, PF, 5 mcg/0.5 mL SARS-CoV-2 virus strain Omicron JN.1 80631-0107-10 CARTON, 10 PRE-FILLED GLASS SYRINGES 80631-0107-01 SYRINGE, PRE-FILLED, 50 mcg/0.5 Ml 91304 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, preservative free, 5 mcg/0.5 mL dosage, for intramuscular useDO NOT FREEZE(*) Vaccines products and codes added to this table have FDA BLA licensure approval or Emergency Use Authorization (EUA).(**) Product Label Tradename: If the manufacturer name is included in the tradename, the vaccine product is provided under EUA. Other tradenames are for vaccine products provided under BLA licensure.Other COVID-19 Vaccine Related Codes and LinksInformation regarding currently active EUA Recipient and Caregiver Fact Sheet URLs and Codes can be found here.Registered users can access COVID-19 vaccine lot numbers and expiration dates provided to CDC by the vaccine manufacturer.Information regarding Previous COVID-19 pandemic Emergency Use Authorization (EUA) and BLA codes and crosswalks can be found here.2024/2025 Seasonal Influenza Codes and CrosswalkThis format includes all seasonal influenza vaccines for the 2024/2025 season in a single Excel crosswalk table that provides the CVX, MVX, NDC Unit of Sale, NDC Unit of Use, and CPT (*) codes for each vaccine.(*) Please note that the CPT codes shown for each vaccine crosswalk are not mapped to the NDC codes, but are mapped to the CVX codes shown. These are reference CPT codes for vaccine categorization and are not intended to represent billable codes.Download the Seasonal Influenza Crosswalk tableInfluenza Vaccines for Season 2024/2025 (Northern Hemisphere)CVX Code CVX Short Description Sale Proprietary Name Sale Labeler MVX Code Unit of Sale NDC11 Unit of Use NDC11 Presentation CPT Code CPT Description141 Influenza, split virus, trivalent, preservative Afluria Seqirus PTY LTD. SEQ 33332-0124-10 33332-0124-11 VIAL, 5 mL, MULTI-DOSE 90658 Influenza virus vaccine, trivalent (IIV3), split virus, 0.5 mL dosage, for intramuscular use90657 Influenza virus vaccine, trivalent (IIV3), split virus, 0.25 mL dosage, for intramuscular use140 Influenza, split virus, trivalent, PF Afluria Seqirus PTY LTD. SEQ 33332-0024-03 33332-0024-04 SYRINGE, 0.5 mL 90656 Influenza virus vaccine, trivalent (IIV3), split virus, preservative free, 0.5 mL dosage, for intramuscular use168 Influenza, adjuvanted, trivalent, PF FLUAD Seqirus, Inc. SEQ 70461-0024-03 70461-0024-04 SYRINGE, 0.5mL 90653 Influenza vaccine, inactivated (IIV), subunit, adjuvanted, for intramuscular use140 Influenza, split virus, trivalent, PF FLUARIX GlaxoSmithKline Biologicals SA SKB 58160-0884-52 58160-0884-41 SYRINGE, 0.5mL 90656 Influenza virus vaccine, trivalent (IIV3), split virus, preservative free, 0.5 mL dosage, for intramuscular use155 Influenza, recombinant, trivalent, PF FLUBLOK TRIVALENT NORTHERN HEMISPHERE Sanofi Pasteur Inc. PMC 49281-0724-10 49281-0724-88 SYRINGE, 0.5 mL 90673 Influenza virus vaccine, trivalent (RIV3), derived from recombinant DNA, hemagglutinin (HA) protein only, preservative and antibiotic free, for intramuscular use153 Influenza, MDCK, trivalent, PF Flucelvax Seqirus Inc. SEQ 70461-0654-03 70461-0654-04 SYRINGE, 0.5 mL 90661 Influenza virus vaccine, trivalent (ccIIV3), derived from cell cultures, subunit, antibiotic free, 0.5 mL dosage, for intramuscular use320 Influenza, MDCK, trivalent, preservative Flucelvax Seqirus Inc. SEQ 70461-0554-10 70461-0554-11 VIAL, 5 mL, MULTI-DOSE 90661 Influenza virus vaccine, trivalent (ccIIV3), derived from cell cultures, subunit, antibiotic free, 0.5 mL dosage, for intramuscular use140 Influenza, split virus, trivalent, PF FLULAVAL ID Biomedical Corporation of Quebec IDB 19515-0810-52 19515-0810-41 SYRINGE, 0.5 mL 90656 Influenza virus vaccine, trivalent (IIV3), split virus, preservative free, 0.5 mL dosage, for intramuscular use135 Influenza, high-dose, trivalent, PF FLUZONE HIGH DOSE NORTHERN HEMISPHERE Sanofi Pasteur Inc. PMC 49281-0124-65 49281-0124-88 SYRINGE, 0.5 mL 90662 Influenza virus vaccine (IIV), split virus, preservative free, enhanced immunogenicity via increased antigen content, for intramuscular use141 Influenza, split virus, trivalent, preservative FLUZONE TRIVALENT NORTHERN HEMISPHERE Sanofi Pasteur Inc. PMC 49281-0641-15 49281-0641-78 VIAL, 5 mL, MULTI-DOSE 90658 Influenza virus vaccine, trivalent (IIV3), split virus, 0.5 mL dosage, for intramuscular use90657 Influenza virus vaccine, trivalent (IIV3), split virus, 0.25 mL dosage, for intramuscular use140 Influenza, split virus, trivalent, PF FLUZONE TRIVALENT NORTHERN HEMISPHERE Sanofi Pasteur Inc. PMC 49281-0424-50 49281-0424-88 SYRINGE, 0.5 mL 90656 Influenza virus vaccine, trivalent (IIV3), split virus, preservative free, 0.5 mL dosage, for intramuscular use111 Influenza, live, trivalent, intranasal FluMist trivalent MedImmune, Inc. MED 66019-0311-10 66019-0311-00 APPLICATOR, 0.2 mL 90660 Influenza virus vaccine, trivalent, live (LAIV3), for intranasal useSouthern Hemisphere 2024 Influenza SeasonCVX Code CVX Short Description Sale Proprietary Name Sale Labeler MVX Code Unit of Sale NDC11 Unit of Use NDC11 Presentation CPT Code CPT Description201 influenza, Southern Hemisphere, preservative free FLUZONE QUADRIVALENT SOUTHERN HEMISPHERE Sanofi Pasteur Inc. PMC 49281-0324-50 49281-0324-88 SYRINGE, 0.5 mL NA NA202 influenza, Southern Hemisphere, quadrivalent, with preservative FLUZONE QUADRIVALENT SOUTHERN HEMISPHERE Sanofi Pasteur Inc. PMC 49281-0398-15 49281-0398-78 VIAL, MULTI-DOSE, 5 mL NA NA231 influenza, Southern Hemisphere, high-dose, quadrivalent FLUZONE High-Dose Quadrivalent Southern Hemisphere Sanofi Pasteur Inc. PMC 49281-0933-50 49281-0933-88 SYRINGE, .7 mL NA NAOn This Page* Respiratory Syncytial Virus (RSV) Codes and Crosswalks* Fall 2024 COVID-19 Vaccine Codes and Crosswalks* Other COVID-19 Vaccine Related Codes and Links* 2024/2025 Seasonal Influenza Codes and CrosswalkRelated PagesView AllBack to Top* Information on Vaccine Data Code Sets* VIS Barcode Lookup Table* VIS to URL Table* Other COVID-19 Vaccine Related Codes* Information on Vaccine Code SetView All Immunization Information Systems (IIS)Other COVID-19 Vaccine Related CodesAugust 26, 2024Sources Print ShareFacebook LinkedIn Twitter SyndicateContent Source:National Center for Immunization and Respiratory DiseasesRelated PagesView All* Information on Vaccine Data Code Sets* VIS Barcode Lookup Table* VIS to URL Table* Other COVID-19 Vaccine Related Codes* Information on Vaccine Code SetView All Immunization Information Systems (IIS)Back to TopImmunization Information Systems (IIS)Immunization information systems (IIS) help providers, families, and public health officials by consolidating immunization information into one reliable source.View All* About IIS* Immunization (IZ) Gateway* Vaccine 2D Barcodes* CDC IIS Activities* Immunization Information Systems Annual Report (IISAR)* IIS Functional Standards v4.1* Functional Standards: Introduction* Functional Standards (v5.0): Introduction* Information on Vaccine Data Code Sets* Core Data Elements* Information on IIS Policy and Legislation* Contacts for IIS Immunization Records* IIS Training Resources* Clinical Decision Support for Immunization (CDSi)* IIS Technical Guidance* IIS Resources and Reference Materials* View AllSign up for Email UpdatesContact UsContact Us* Call 800-232-4636* Contact CDCAbout CDCAbout CDC* Pressroom* Organization* Budget & Funding* Careers & JobsPolicies* Accessibility* External Links* Privacy* Web Policies* FOIA* OIG* No Fear Act* Nondiscrimination* Vulnerability Disclosure PolicyLanguagesLanguages* EspañolLanguage Assistance* Español* 繁體中文* Tiếng Việt* 한국어* Tagalog* Русский* العربية* Kreyòl Ayisyen* Français* Polski* Português* Italiano* Deutsch* 日本語* فارسی* EnglishArchive* CDC Archive* Public Health PublicationsContact UsContact Us* Call 800-232-4636* Contact CDCAbout CDC* Pressroom* Organization* Budget & Funding* Careers & Jobs* About CDCPolicies* Accessibility* External Links* Privacy* Web Policies* FOIA* OIG* No Fear Act* Nondiscrimination* Vulnerability Disclosure PolicyLanguagesLanguages* EspañolLanguage Assistance* Español* 繁體中文* Tiếng Việt* 한국어* Tagalog* Русский* العربية* Kreyòl Ayisyen* Français* Polski* Português* Italiano* Deutsch* 日本語* فارسی* EnglishArchive* CDC Archive* Public Health PublicationsHHS.gov USA.gov
Note: Comparison ignores leading/trailing whitespace
and certain script/tracking codes. Word-level
highlighting (optional above) only applies to changed
lines.